Innovative MedTech Inc (IMTH) reported QQ2 2024 revenue of $432,692 thousand with a gross profit of $424,891 thousand, yielding an exceptionally high gross margin of 98.20%. Despite the top-line level showing YoY growth of 2.94% and QoQ decline of 9.99%, the company remains unprofitable on a bottom-line basis, posting a net loss of $188,000 thousand and an EBITDA of $(126,000) thousand for the quarter. Operating income was $(93,834) thousand, and earnings per share stood at $(0.01). The quarter continued to burn cash, with net cash from operating activities of $(134,487) thousand and a cash balance at period-end of $92,509 thousand. The balance sheet shows pronounced leverage and limited liquidity: total liabilities of $5,968,391 thousand versus total assets of $4,329,646 thousand, producing a negative stockholders’ equity of $(1,638,745) thousand. Net debt stood at $(3,696,126) thousand, and the current ratio was a critically stressed 0.0785x. Management commentary is not contained in the provided transcript data, limiting the ability to quote verbatim management sentiment; as such, the analysis relies on reported metrics and industry context to frame the outlook.